Therapy Areas: Oncology
Illumina partners with Roche to broaden patient access to genomic testing
14 January 2020 -

DNA sequencing company Illumina Inc (NASDAQ:ILMN) said on Monday that it plans to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology under a non-exclusive collaboration agreement with Roche, a pharmaceuticals company.

NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. This agreement brings together complementary capabilities of each company to broaden global adoption of NGS in cancer care.

Under the terms of the 15 year agreement, Illumina will grant Roche with rights to develop and distribute in-vitro diagnostic (IVD) tests on Illumina's NextSeq 550Dx System, as well as on its future portfolio of diagnostic (Dx) sequencing systems, including NovaSeqDx.

In conjunction with the agreement, Roche will collaborate with Illumina to complement Illumina's comprehensive pan-cancer assay, TruSight Oncology 500 (TSO 500), with new companion diagnostic (CDx) claims.

The financial terms of the deal were not disclosed by the companies.